ADIAL PHARMACEUTICALS, INC. (ADIL) is a publicly traded company in the Unknown sector. Across all available filings, 9 corporate insiders have executed 60 transactions totaling $1.4M, demonstrating a bearish sentiment with -$495.7K in net insider flow. The most recent transaction on Sep 29, 2023 involved a purchase of 700 shares valued at $1.9K.
No significant insider buying has been recorded for ADIL in the recent period.
No significant insider selling has been recorded for ADIL in the recent period.
Based on recent SEC filings, insider sentiment for ADIL is bearish with an Insider Alignment Score of 32/100 and a net flow of -$495.7K. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at ADIAL PHARMACEUTICALS, INC. (ADIL) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 9 insiders are actively trading ADIL stock, having executed 60 transactions in the past 90 days. The most active insider is Bankole A. Johnson (Executive), who has made 9 transactions totaling $1.2M.
Get notified when executives and directors at ADIL file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Sep 29, 2023 | Schuyler Kevin | Executive | Purchase | 700 | $2.74 | $1.9K | |
| May 23, 2023 | J. Claiborne Cary | Executive | Award | 420,000 | $N/A | $0 | |
| May 23, 2023 | B. Stilley William III | Executive | Award | 240,800 | $N/A | $0 | |
| May 23, 2023 | Truluck Joseph | Executive | Award | 157,500 | $N/A | $0 | |
| Dec 30, 2022 | B. Stilley William III | Executive | Disposition | 166,667 | $N/A | $0 | |
| Sep 20, 2022 | J. Claiborne Cary | Executive | Award | 75,000 | $0.42 | $31.5K | |
| Sep 19, 2022 | J. Claiborne Cary | Executive | Award | 25,000 | $0.43 | $10.8K | |
| Aug 18, 2022 | J. Claiborne Cary | Executive | Award | 1,000,000 | $N/A | $0 | |
| Feb 23, 2022 | B. Stilley William III | Executive | Award | 250,000 | $N/A | $0 | |
| Dec 30, 2021 | W. Newman James Jr | Executive | Purchase | 10,000 | $2.71 | $27.1K | |
| Dec 30, 2021 | W. Newman James Jr | Executive | Purchase | 5,000 | $2.72 | $13.6K | |
| Dec 30, 2021 | W. Newman James Jr | Executive | Purchase | 10,000 | $2.66 | $26.6K | |
| Dec 23, 2021 | Schuyler Kevin | Executive | Gift | 312,990 | $N/A | $0 | |
| Nov 30, 2021 | B. Stilley William III | Executive | Purchase | 10,600 | $2.75 | $29.1K | |
| Nov 29, 2021 | B. Stilley William III | Executive | Purchase | 10,000 | $2.59 | $25.9K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 4 | $948.5K | 62.8% |
Purchase(P) | 24 | $452.8K | 30.0% |
Conversion(C) | 8 | $67.4K | 4.5% |
Award(A) | 14 | $42.3K | 2.8% |
Disposition(D) | 1 | $0 | 0.0% |
Gift(G) | 1 | $0 | 0.0% |
Other(J) | 8 | $0 | 0.0% |
Insider selling pressure at ADIAL PHARMACEUTICALS, INC. has increased, with 9 insiders executing 60 transactions across all time. Total sales of $948.5K significantly outpace purchases of $452.8K, resulting in a net outflow of $495.7K. This selling activity appears largely discretionary, which may warrant closer attention from investors.